Where does Envision Diagnostics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Envision Diagnostics, Inc. ranks #31,558 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Envision Diagnostics, Inc. hold?

Envision Diagnostics, Inc. holds 8 US utility patents granted between 2016 and 2025, spanning 2 technology areas.

What is Envision Diagnostics, Inc.'s Innovation Score?

Envision Diagnostics, Inc. has an Innovation Score of 26.9 out of 100 (22nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Envision Diagnostics, Inc. focus on?

Envision Diagnostics, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 7 patents, ranking #2,341 of 7,127 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Envision Diagnostics, Inc.'s patent grant rate increasing or decreasing?

Envision Diagnostics, Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Envision Diagnostics, Inc.'s patents?

Envision Diagnostics, Inc.'s patents average 18.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Envision Diagnostics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Envision Diagnostics, Inc.

USPTO PatentsView assignee record - 8 granted patents across 2 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Envision ranks #31,558 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 2 technology areas.

#31,558
of 49,997 US assignees by volume: 22nd percentile
by Innovation Score (26.9/100): 18.3
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31558 · US Corporation #31,558 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,558/49,997
PHOTO-FINISH Entera Bio
CPC-NARROW A61B · 2 areas
INNOV-THIN 26.9/100
CLAIMS-RICH 18.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Entera Bio Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Envision’s 26.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (28%) Velocity 3.3 pts (12%) Breadth 5.0 pts (19%) Claim depth 11.0 pts (41%)

Qualcomm Incorporated · highest

85
Envision Diagnostics · this assignee

27
3D Lighting… · lowest

7

What this shows Envision's Innovation Score is 26.9/100 (22nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Envision?

Each dot is one of Envision’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Envision’s own 18.3 claims/patent is ABOVE the 17.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Envision vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Envision's grants concentrate

Envision Diagnostics, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 87.5% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2016. By volume, Envision sits between Entera Bio Ltd. and Eugen Seitz AG.

Envision's three-year grant acceleration

Envision Diagnostics, Inc. shows 2 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Entera Bio

8
Enterin

8
Enteris Biopharma

8
Envirokure

8
Enz Technik

8
Escher Group (IRL)

8
Espervita Therape…

8
Eugen Seitz

8
Envision Diagnost… ◀

8

What this shows Envision holds 8 patents at rank #31,578, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Envision

By rank, the assignees closest to #31,578 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Envision's primary technology class.

Envision's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 22nd percentile higher than 22% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Envision Diagnostics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	12.5%
2019	1	12.5%
2020	2	25.0%
2021	1	12.5%
2023	2	25.0%
2025partial year	1	12.5%

Which technologies does Envision Diagnostics, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 7

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Envision Diagnostics, Inc.'s patent record in context - here's where to go next.

Envision Diagnostics, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 87.5% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #31,558 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Envision Diagnostics, Inc. against Entera Bio Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.